| 引用本文: | 阙万才,程昱,赵志常,曾晓芳,张冰清,刘茂柏,丘宏强.头孢他啶/阿维巴坦耐药肺炎克雷伯菌的体外抗菌药物治疗方案研究[J].中国现代应用药学,2021,38(12):1502-1508. |
| QUE Wancai,CHENG Yu,ZHAO Zhichang,ZENG Xiaofang,ZHANG Bingqing,LIU Maobai,QIU Hongqiang.Study on the in Vitro Antibacterials Therapy of Ceftazidime/Avibactam-resistant Klebsiella Pneumoniae[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(12):1502-1508. |
|
| 本文已被：浏览 1449次 下载 567次 |
码上扫一扫！ |
|
|
| 头孢他啶/阿维巴坦耐药肺炎克雷伯菌的体外抗菌药物治疗方案研究 |
|
阙万才1, 程昱1, 赵志常1, 曾晓芳1, 张冰清2, 刘茂柏1, 丘宏强1,2
|
|
1.福建医科大学附属协和医院药学部, 福州 350001;2.福建医科大学药学院, 福州 350108
|
|
| 摘要: |
| 目的 探索对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌体外抗菌药物治疗方案，为临床治疗方案选择提供理论依据。方法 采用PCR对2株肺炎克雷伯菌株可能耐药基因进行鉴定，并对扩增产物进行测序。采用体外时间杀菌试验评估不同抗菌药物单药或联合用药对耐药菌株生长的影响。结果 膜孔蛋白严重缺失和产金属酶分别介导了两菌株对头孢他啶/阿维巴坦耐药；多黏菌素B、亚胺培南、美罗培南和磷霉素单药或两药合并不能显示足够抗菌效果，而多黏菌素B-美罗培南-磷霉素或多黏菌素B-头孢他啶-阿维巴坦三药联合方案可分别对这2株耐药株产生强大持续的杀菌作用。结论 多黏菌素B为基础三药联合可能是对抗具有不同机制介导的头孢他啶/阿维巴坦耐药肺炎克雷伯菌的有效方案。 |
| 关键词: 头孢他啶|阿维巴坦|耐药|肺炎克雷伯菌|体外 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.12.017 |
| 分类号:R969.4 |
| 基金项目:福建省卫生计生中青年骨干人才培养项目（2018-ZQN-35）；福建省科技厅社发处引导性项目（2016Y0045）；福建省科技创新联合资金项目（2019Y9051） |
|
| Study on the in Vitro Antibacterials Therapy of Ceftazidime/Avibactam-resistant Klebsiella Pneumoniae |
|
QUE Wancai1, CHENG Yu1, ZHAO Zhichang1, ZENG Xiaofang1, ZHANG Bingqing2, LIU Maobai1, QIU Hongqiang1,2
|
|
1.Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China;2.College of Pharmacy, Fujian Medical University, Fuzhou 350108, China
|
| Abstract: |
| OBJECTIVE To explore the antibacterial therapy of ceftazidime/avibactam-resistant Klebsiella pneumoniae strains in vitro and to provide a basic theory for the clinical treatment against such resistant strains. METHODS The possible resistance genes of two Klebsiella pneumoniae strains were characterized by PCR, and then the amplicons were sequenced. The effect of monotherapy and combination of the different antibiotics against the resistant strains were evaluated by in vitro time-kill experiments. RESULTS Deficiency of outer membrane porins and production of metallo-beta-lactamase mediated the two strains to ceftazidime/avibatan-resistant, respectively. The time-kill experiment results showed that monotherapy and two-drug combinations of polymyxin B, imipenem, meropenem and fosfomycin could not obtain a satisfactory bactericidal effect. However, the triple therapy of polymyxin B-meropenem-fosfomycin or polymyxin B-ceftazidime-averbactam could produce strong and sustained bactericidal effect on the two drug-resistant strains respectively. CONCLUSION Different triple therapy based on polymyxin B may be an effective strategy against ceftazidime/avibactam-resistant Klebsiella pneumonia strains underlying a different resistant mechanism. |
| Key words: ceftazidime|avibactam|resistance|Klebsiella pneumoniae|in vitro |
